OptimizeRx Q3 sales fall on contracted revenue; lowers annual revenue outlook
OPRX•OptimizeRx’s third-quarter revenue fell 17% year over year to $21.6 million but beat analyst expectations; adjusted EPS of $0.20 and adjusted EBITDA of $6.3 million also topped estimates. The company lowered its 2026 revenue outlook to $87 million-$93 million, citing lower contracted revenue, while maintaining adjusted EBITDA guidance of $21 million-$25 million.
1. Quarterly results
OptimizeRx reported third-quarter revenue of $21.6 million, down 17% year over year and above the $21.19 million analyst consensus. Adjusted EPS was $0.20 versus the $0.17 consensus, and adjusted EBITDA was $6.3 million compared with estimates of $4.1 million.
2. Updated outlook
The company lowered its 2026 revenue guidance to $87 million-$93 million, citing lower contracted revenue, and maintained its adjusted EBITDA guidance of $21 million-$25 million. It cited renewed fourth-quarter spending from a previously significant customer and pent-up demand for the 2027 RFP season.
3. Margin expansion
OptimizeRx said adjusted EBITDA margin expanded by more than 900 basis points, citing improved product mix and cost management initiatives.
